Global Leading Market Research Publisher QYResearch announces the release of its latest report “Sodium Citrate Solution for Anticoagulation - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Sodium Citrate Solution for Anticoagulation market, including market size, share, demand, industry development status, and forecasts for the next few years.

For healthcare providers, nephrology departments, and blood collection centers, the management of anticoagulation during extracorporeal procedures—such as continuous renal replacement therapy (CRRT), hemodialysis, and source plasma collection—requires balancing effective clot prevention with patient safety. Traditional anticoagulants like heparin, while effective, carry risks of systemic bleeding, heparin-induced thrombocytopenia (HIT), and other complications that limit their use in critically ill patients. Sodium citrate solution for anticoagulation addresses these challenges with regional citrate anticoagulation (RCA) technology specifically used for extracorporeal anticoagulation. The principle involves infusing sodium citrate at the arterial end of the extracorporeal circulation, where it chelates plasma calcium ions to form soluble, poorly dissociable calcium citrate—significantly reducing ionized calcium levels in the extracorporeal circuit and inhibiting coagulation. Simultaneously, calcium supplementation through peripheral veins maintains stable ionized calcium levels and normal coagulation function in the body. This regional approach offers lower bleeding risk compared to heparin, reduces HIT incidence, and demonstrates excellent biocompatibility. The global market for sodium citrate solution for anticoagulation was valued at US$ 201 million in 2025 and is projected to grow at a CAGR of 4.3% to reach US$ 268 million by 2032, driven by increasing adoption of CRRT in intensive care units, expanding source plasma collection activities, and the shift toward safer anticoagulation alternatives. In 2024, global sales reached approximately 108 million units, with an average market price of US$ 1.8 per unit.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6096906/sodium-citrate-solution-for-anticoagulation

Market Definition and Product Segmentation
Sodium citrate solution for anticoagulation represents a specialized category within the anticoagulant market, distinguished by its regional mechanism of action that provides localized anticoagulation in the extracorporeal circuit while preserving systemic hemostasis. This technology is widely used in continuous renal replacement therapy, hemodialysis, and source plasma collection.

Concentration Segmentation
The market is stratified by volume and concentration, each addressing distinct clinical requirements:

200ml:8g: The dominant segment for high-volume applications, providing standardized concentration for CRRT and plasma collection procedures where precise citrate delivery is essential.

160ml:6.4g: The established segment for standard clinical applications, offering balanced volume and concentration for routine dialysis and apheresis procedures.

100ml:4g: The specialized segment for smaller-volume applications, including pediatric procedures and applications where lower total volume is preferred.

Application Segmentation
The market serves critical healthcare settings:

Hospital: The largest segment, encompassing intensive care units (ICU) where CRRT is used for acute kidney injury, sepsis, and fluid management; dialysis units; and surgical departments.

Blood Bank: Serving source plasma collection centers where citrate anticoagulation is essential for plasma collection and donor safety.

Other: Including apheresis centers and specialized clinical applications.

Competitive Landscape
The sodium citrate solution market features a competitive landscape combining global medical device leaders with specialized pharmaceutical manufacturers. Key players include Zimmer Biomet, Terumo BCT, Fresenius Kabi, Chengdu Qingshan Likang Pharmaceutical, Sichuan Mianzhu Hongji Pharmaceutical, Haier Haematologi, and Tianjin Jinyao Pharmaceutical.

Industry Development Characteristics
1. CRRT Adoption in Intensive Care

A case study from QYResearch's industry monitoring reveals that continuous renal replacement therapy (CRRT) has become standard of care for critically ill patients with acute kidney injury. Regional citrate anticoagulation is the preferred anticoagulation method for CRRT due to its lower bleeding risk, extended filter life, and reduced HIT incidence compared to heparin.

2. Safety Advantages Over Heparin

Regional citrate anticoagulation offers significant safety advantages. A case study from the critical care sector indicates that citrate anticoagulation reduces major bleeding events, eliminates the risk of heparin-induced thrombocytopenia, and enables therapy in patients with heparin allergies or contraindications—expanding the patient population that can safely receive extracorporeal therapies.

3. Source Plasma Collection Growth

The expansion of source plasma collection for fractionation into immunoglobulin, albumin, and coagulation factor therapies has driven demand for citrate anticoagulation solutions. A case study from the plasma industry indicates that citrate is the standard anticoagulant for apheresis-based plasma collection, with collection volumes increasing globally.

4. Biocompatibility and Filter Lifespan

Citrate anticoagulation improves circuit biocompatibility and extends filter life. A case study from the dialysis sector indicates that citrate reduces inflammation associated with extracorporeal circuits and prevents clotting, enabling longer filter use and reducing treatment interruptions.

Exclusive Industry Insights: The Regional Anticoagulation Advantage
Our proprietary analysis identifies the regional anticoagulation mechanism as the defining advantage of citrate therapy. By providing anticoagulation only in the extracorporeal circuit—where clotting would obstruct the circuit—while preserving systemic coagulation, citrate enables therapy for patients who would be at excessive bleeding risk with systemic anticoagulants. This regional mechanism is particularly valuable in intensive care settings where patients often have multiple bleeding risk factors.

Strategic Outlook
For industry executives, investors, and marketing leaders evaluating opportunities in the sodium citrate solution for anticoagulation market, the projected 4.3% CAGR reflects sustained demand from CRRT adoption, source plasma collection growth, and the shift toward safer anticoagulation alternatives. Manufacturers positioned to capture disproportionate share share three characteristics: demonstrated expertise in sterile pharmaceutical manufacturing and quality systems; product portfolios spanning multiple volume/concentration configurations; and established relationships with hospital ICUs, dialysis centers, and blood collection organizations. As the market evolves toward integrated citrate delivery systems and expanded applications in extracorporeal therapies, the ability to deliver reliable, safe, and consistent anticoagulation solutions will define competitive leadership.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp